Bawiskar Nipun, Acharya Sourya, Kumar Sunil
Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research (Deemed to be University), Wardha, Maharashtra, India.
J Family Med Prim Care. 2024 Aug;13(8):2857-2862. doi: 10.4103/jfmpc.jfmpc_1863_21. Epub 2024 Jul 26.
Metabolic dysfunction associated fatty liver disease (MAFLD) was a concept suggested lately. Initially, the only criterion for the diagnosis of MAFLD was the absence of alcohol intake. With rising prevalence and studies assessing this condition, certain "positive criteria" were put forth. Experts from 22 countries proposed a simple yet comprehensive definition for the condition independent of other liver diseases. The presence of hepatic steatosis in addition to diabetes mellitus type 2, metabolic dysregulation, and obesity is generally observed. Criteria to define MAFLD-associated cirrhosis were also proposed. Reaching an agreement on MAFLD criteria will help define a protocol (for example: for International classification of Diseases (ICD) - coding), which will improve clinical care and advance the clinical and scientific field of liver research. As it is a condition that increases the risk of diabetes mellitus, chronic kidney disease (CKD), cirrhosis, hepatocellular carcinoma, and cardiac disorders it is important to recognize it at an early stage which makes it essential part of family medicine and primary care.
代谢功能障碍相关脂肪性肝病(MAFLD)是最近提出的一个概念。最初,MAFLD诊断的唯一标准是无酒精摄入。随着患病率的上升以及对该疾病评估研究的开展,提出了某些“阳性标准”。来自22个国家的专家针对该疾病提出了一个简单而全面的定义,该定义独立于其他肝脏疾病。通常观察到除2型糖尿病、代谢失调和肥胖外,还存在肝脂肪变性。还提出了定义MAFLD相关肝硬化的标准。就MAFLD标准达成共识将有助于确定一个方案(例如:用于国际疾病分类(ICD)编码),这将改善临床护理并推动肝脏研究的临床和科学领域发展。由于该疾病会增加患糖尿病、慢性肾脏病(CKD)、肝硬化、肝细胞癌和心脏疾病的风险,早期识别它很重要,这使其成为家庭医学和初级保健的重要组成部分。